Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Q3 FY25 Earnings Presentation
27 slides from Viyash Scientific's earnings presentation, Feb 11, 2025
Slide 1: Stock exchange covering letter for investor presentation
Proven Ability In Life Sciences February 11, 2025 BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex, Dalal Street, Fort, Bandra (East), Mumbai – 400 001. Mumbai – 400 051. Scrip co
Slide 2: Investor Presentation Q3 FY25
INVESTOR PRESENTATION Q3 FY25 SEQUENT SCIENTIFIC LIMITED 11th Feb 2025
Slide 3: Sequent Q3 FY25 – Continued growth in revenue and profitability
Sequent Q3 FY25 – Continued growth in revenue and profitability The performance of SeQuent in Q3 FY25 continues to build on the company’s strong return to growth and profitability across all parts of the business. We remain positive on the sustenance of the current momentum. This is further strength
Slide 4: SeQuent & Viyash: Proforma Q3FY25 Combined Performance
SeQuent & Viyash : Proforma Q3FY25 Combined Performance
Slide 5: Q3 FY25 Performance Highlights
Q3 FY25 Performance Highlights All values in ₹ Mn Net Debt to LTM Revenues EBITDA (pre- ESOP)1 EBITDA margin Adj. EBITDA1 ₹7,747 ₹1,179 15.2% 1.2x Million Million 435 18.8% 66.3% vs. 1.4x YoY YoY bps in Q2FY25 YoY Proforma Q3FY25 Combined Performance 4 Notes: 1. EBITDA for Viyash is adjusted for ESO
Slide 6: 9M FY25 Performance Highlights
9M FY25 Performance Highlights All values in ₹ Mn Net Debt to LTM Revenues EBITDA (pre- ESOP)1 EBITDA margin Adj. EBITDA1 ₹22,369 ₹3,317 14.8% 1.2x Million Million 485 12.0% 66.6% vs. 1.4x YoY YoY bps in Q2FY25 YoY Proforma Q3FY25 Combined Performance 5 Notes: 1. EBITDA for Viyash is adjusted for ES
Slide 7: SeQuent: Q3FY25 Performance Update
SeQuent : Q3FY25 Performance Update
Slide 8: Q3 FY25 Performance Highlights – Sustained Revenue and Profit Growth
Q3 FY25 Performance Highlights – Sustained Revenue and Profit Growth Strengthening Our Position All values in ₹ Mn Revenues EBITDA (Pre ESOP) EBITDA margin PBT ₹3,908 ₹494 12.6% ₹81 Million Million Million 348 18.7% 63.8% 444% YoY YoY bps YoY YoY 7
Slide 9: 9M FY25 - Robust Revenue and EBITDA Growth
9M FY25 - Robust Revenue and EBITDA Growth, Fueling Momentum for a Successful Year All values in ₹ Mn Revenues EBITDA (Pre ESOP) EBITDA margin PBT ₹11,497 ₹1,424 12.4% ₹280 Million Million Million 590 14.0% 116.5% 149% YoY YoY bps YoY YoY 8
Slide 10: SeQuent: Q3 FY25 Revenue Performance – by geography
SeQuent : Q3 FY25: Revenue Performance – by geography All values in ₹ Mn QnQ Gr% YoY Gr% YoY Gr% Revenue Distribution Q3 FY25 Q2 FY25 QnQ Gr% (In cc) Q3 FY24 YoY Gr% (In cc) 9M FY25 9M FY24 YoY Gr% (In cc) Formulations 3,008 2,836 6.1% 8.9% 2,510 19.8% 19.2% 8,849 7,520 17.7% 21.9% Europe 1,334 1,33
Slide 11: SeQuent: Q3 FY25 Business Performance
SeQuent : Q3 FY25 Business Performance All values in ₹ Mn Europe: Turkish GMP certification received 1,000+ FDFs Emerging Markets: Business restructuring focused on volume recovery Formulations LATAM: Strong growth driven by strategic portfolio focus 90+ Countries India : Project Udaan field expansi
Slide 12: SeQuent: Q3 FY25 Consolidated Financials
SeQuent : Q3 FY25 Consolidated Financials All values in ₹ Mn Key Notes : Q3 Q2 Q3 Grw QnQ Grw YoY 9M 9M Grw YoY Particulars FY25 FY25 FY24 % % FY25 FY24 % + 3.0% Gross Margin and +3.4% EBITA Revenue from Operations 3,908 3,686 3,294 6.0% 18.7% 11,497 10,085 14.0% Margin Improvement YoY in Q3 FY25: •
Slide 13: Viyash: Business Update
Viyash Viyash: Business Update
Slide 14: Viyash: Q3 FY25 – Continued strong performance on revenue, profitability and cashflows
Viyash: Q3 FY25 – Continued strong performance on revenue, profitability and cashflows Net Debt to LTM Revenues Adj. EBITDA1 EBITDA margin Adj. EBITDA1 ₹3,839 ₹685 17.8% 0.4x Million Million 520 19.0% 68.0% vs.1.1x YoY YoY bps In FY24 YoY 13 Notes: 1. EBITDA is adjusted for ESOP costs, accelerated v
Slide 15: Viyash: 9M FY25 – Robust YTD performance
Viyash: 9M FY25 – Robust YTD performance Net Debt to LTM Revenues Adj. EBITDA1 EBITDA margin Adj. EBITDA1 ₹10,872 ₹1,893 17.4% 0.4x Million Million 395 9.9% 42.1% vs.1.1x YoY YoY bps In FY24 YoY 14 Notes: 1. EBITDA is adjusted for ESOP costs, accelerated vesting of warrants, call option charge and m
Slide 16: Key updates from Q3 FY25
Key updates from Q3 FY25 Facility Inspections Regulatory Approvals Launches 1 Regulatory Audits 3 APIs: CEP (2), CA (1) 2 FDFs- US 40 Customer audits 2 FDFs: US (2) Products Filed Validations Completed R&D Pipeline 03 APIs: USDMF (1), 4 Validations 25+ products CEP (1), EDMF(1) 15 Source: Viyash Lif
Slide 17: Extensive Manufacturing Capabilities (1/2)
Extensive Manufacturing Capabilities (1/2) VIYASH UNIT - I Containment facility for in-house SYMED LABS LTD, UNIT-I Operates in accordance APPCO PHARMA LLC manufacturing of high potent with cGMP (OEB 4/5) and cytotoxic API. Capacity-80KL Capacity-39KL USFDA/ EU-GMP/ PMDA/ USFDA/ EU-GMP/ WHO- TGA/ KF
Slide 18: Extensive Manufacturing Capabilities (2/2)
Extensive Manufacturing Capabilities (2/2) SYMED LABS LTD, UNIT-IV Expertise in Grignard, Acid Derivatives VINDHYA PHARMA Expertise in Grignard, Coupling, Bromination, carbonylation, Iron Complex reactions, Hydrolysis, Reduction, Chlorination, Reduction reactions in Catalytic Media, Condensation, Ac
Slide 19: Viyash: Financial performance
Viyash: Financial performance All values in ₹ Mn Q3 Q3 Q2 Grw QoQ 9M YTD 9M YTD Particulars Grw YoY % Grw YoY % FY25 FY24 FY25 % FY25 FY242 Revenue from Operations 3,839 3,226 19.0% 3,632 5.7% 10,872 9,896 9.9% Material Consumption (1,751) (1,443) 21.4% (1,624) 7.8% (4,956) (4,721) 5.0% Gross Profit
Slide 20: Merger Update
Merger Update bo
Slide 21: Q3FY25: Combined business performance
Q3FY25: Combined business performance Q3 FY25 YoY Growth % SeQuent Combined (For the quarter) (Combined) Revenue 3,839 3,908 7,747 18.8% (INR Mn) EBITDA1 685 494 1,179 66.3% (INR Mn) EBITDA Margin % 17.8% 12.6% 15.2% +435bps Net Debt to LTM 0.4x 2.1x 1.2x EBITDA 20 Notes: 1. EBITDA for Viyash is adj
Slide 22: 9MFY25: Combined business performance
9MFY25: Combined business performance 9M YTD FY25 YoY Growth % SeQuent Combined (For the quarter) (Combined) Revenue 10,872 11,497 22,369 12.0% (INR Mn) EBITDA1 1,893 1,424 3,317 66.6% (INR Mn) EBITDA Margin % 17.4% 12.4% 14.8% +485bps Net Debt to LTM 0.4x 2.1x 1.2x EBITDA 21 Notes: 1. EBITDA for Vi
Slide 23: Merger – Process Update
Merger – Process Update Merger process status update • CCI approval received • Stock exchange NOC process underway - scheme under review by SEBI and final NOC awaited • Upon receipt of NOC, NCLT filing to be made • Other regulatory approvals, if any to follow Expected timelines for the completion of
Slide 24: Synergy Update
Synergy Update Synergy Planning 4 Core synergy areas identified Synergy Realization Timeline (Months) Process on Track ✓ CCI approval received Till Merger Area 0-6 6-12 12+ Approval ✓ Senior management teams have identified & R&D prioritized synergy Leverage Viyash’s R&D team & IP focus; resource ar
Slide 25: Appendix
Appendix
Slide 26: Combined P&L – Snapshot
Combined P&L – Snapshot Viyash SeQuent Combined Key Notes : Particulars FY24 9MFY25 FY24 9MFY25 FY24 9MFY25 Revenue from Operations 13,110 10,872 13,697 11,497 26,807 22,369 ESOP cost, Exceptional items and Material Consumption (6,142) (4,956) (7,597) (6,121) (13,739) (11,077) amortization of acquis
Slide 27: For details, feel free to contact
For details, feel free to contact: Yoshita Vora Abhishek Singhal Company Secretary Investor Relations Consultant +91 22 4111 4777 abhishek@arunya.co.in investorrelations@sequent.in Registered Office: 301/A, ‘Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Maharashtra, In